Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island, has purchased and installed New York’s first clinical LumaGEM Molecular Breast Imaging (MBI) system.

The PACS Administrators Registry and Certification Association (PARCA) recently announced it is adding a certification and certification exams for DICOM, the international standard for Digital Imaging and Communications in Medicine. The new certification will replace the Certified PACS Interface Analyst (CPIA) certification.

The newest release of American College of Radiology (ACR) Appropriateness Criteria covers 230 topics with more than 1,100 clinical indications.

March 31, 2017 — A recent analysis of newly added 2014 data to the National Cancer Institute SEER database by R. Edward ...

The Connecticut Hospital Association (CHA) and Bayer announced an alliance to establish the United States' first-ever statewide radiation dose management repository for patients undergoing certain radiological procedures. The repository will use Bayer’s Radimetrics, a radiation and contrast dose management and analytics tool which provides clinicians with data needed for them to help ensure their patients receive the lowest radiation dosage necessary. The goal is for clinicians to be able to share the data in order to benchmark radiation exposure.

Radiology-TEACHES, an online portal led by principal investigator Marc H. Willis, DO, recently earned the American Board of Internal Medicine (ABIM) Foundation, Costs of Care and Leapfrog Group Creating Value Challenge “Teaching Value” Award.

March 29, 2017 — Rayence Inc. announced that its new C-Series digital radiography (DR) detectors have recently been ...

EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity focused ultrasound) for prostate tissue ablation in patients who had previously undergone radiotherapy treatment. The article concludes that HIFU should be considered as a valuable therapeutic option for carefully selected patients who failed a previous radiotherapy treatment. The article was published in the January 2017 edition of the British Journal of Urology International.

Results from a prospective clinical trial showed a blood test looking at specific biomarkers was able to detect lung cancer recurrences an average of six months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating tumor cells (CTC) as biomarkers for locally advanced lung cancer, the findings indicate that blood tests potentially can be used in conjunction with computed tomography (CT) and positron emission tomography (PET)/CT scans to guide personalized treatment planning for patients with non-small cell lung cancer (NSCLC). The study was presented at the 2017 Multidisciplinary Thoracic Cancers Symposium, March 16-18 in San Diego.